Lansdowne Partners (UK)’s Summit Therapeutics SMMT Stock Holding History

Lansdowne Partners (UK)’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,667,350	Closed	-$7.92M	–	52
2020 Q2	$7.92M	Sell	2,667,350 -1,561,350	-37%	-$5.38M	0.33%	31
2020 Q1	$10M	Buy	4,228,700 +2,632,034	+165%	+$4.52M	0.56%	20
2019 Q4	$2.56M	Hold	1,596,666	–	–	0.07%	24
2019 Q3	$2.86M	Hold	1,596,666	–	–	0.08%	29
2019 Q2	$2.02M	Hold	1,596,666	–	–	0.05%	27
2019 Q1	$2.92M	Hold	1,596,666	–	–	0.06%	32
2018 Q4	$1.84M	Hold	1,596,666	–	–	0.03%	34
2018 Q3	$3.54M	Hold	1,596,666	–	–	0.04%	34
2018 Q2	$3.91M	Hold	1,596,666	–	–	0.04%	39
2018 Q1	$20.6M	Hold	1,596,666	–	–	0.21%	18
2017 Q4	$17.7M	Hold	1,596,666	–	–	0.16%	23
2017 Q3	$20M	Buy	1,596,666 +666,666	+72%	+$8.64M	0.21%	18
2017 Q2	$10.6M	Hold	930,000	–	–	0.09%	24
2017 Q1	$12.3M	Hold	930,000	–	–	0.11%	22
2016 Q4	$7.96M	Hold	930,000	–	–	0.07%	21
2016 Q3	$8.43M	Hold	930,000	–	–	0.07%	20
2016 Q2	$7.52M	Hold	930,000	–	–	0.07%	22
2016 Q1	$6.34M	Hold	930,000	–	–	0.05%	23
2015 Q4	$10.7M	Hold	930,000	–	–	0.07%	23
2015 Q3	$9.68M	Hold	930,000	–	–	0.08%	22
2015 Q2	$9.82M	Hold	930,000	–	–	0.08%	23
2015 Q1	$11.5M	Buy	+930,000	New	+$10.5M	0.1%	21

Other funds holding SMMT

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BBR Partners New York $2.13B AUM 21.87% 1-Year Est. Return

MFS

Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Lansdowne Partners (UK)'s SMMT Position: Q3 2020 in Review

Lansdowne Partners (UK) sold out of Summit Therapeutics (SMMT) in Q3 2020, closing a stake of 2,667,350 shares — an estimated $7.92M sold.

Lansdowne Partners (UK) first reported a position in SMMT in Q1 2015 and held it in 22 quarters. The position peaked at $20.6M in Q1 2018. 19 funds tracked by Wall St. Rank hold SMMT as of Q3 2020.

Lansdowne Partners (UK) reported no remaining Summit Therapeutics position as of Q3 2020 after selling out during the quarter.
Lansdowne Partners (UK) sold 2,667,350 Summit Therapeutics shares in Q3 2020, an estimated $7.92M.
Lansdowne Partners (UK) first reported a position in Summit Therapeutics in Q1 2015 and held it in 22 quarters.
Lansdowne Partners (UK)'s Summit Therapeutics position peaked at $20.6M in Q1 2018.
19 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2020.

Based on Lansdowne Partners (UK)'s 13F filing for Q3 2020, filed 16 Nov 2020.